The Situation
A 61-year-old patient was prescribed Mycophenolate for the management of IGF Vasculitis. EmpiRx Health’s Population Health Management engine identified that this medication was not FDA approved for the condition. Upon review of the chart notes, it was identified that the patient was taking another medication, Humira, which carries a potential warning of IGF Vasculitis. Humira was prescribed for the management of rheumatoid arthritis.
The Intervention
Our Clinical Pharmacist assessed the patient’s chart notes, and engaged the prescribing physician to discuss the potential that the patient’s condition may be drug induced. The prescriber collaborated with the patient’s rheumatologist who prescribed the Humira, and both agreed that discontinuing Humira was in the patient’s best interest given the clinical evidence provided. The patient utilized over-the-counter medications to manage the rheumatoid arthritis.
Results Matter:
By identifying the potential for drug-induced disease, we were able to prevent potentially serious adverse reactions and eliminate wasteful spending, while improving the patient’s health.
- Original Prescription: Mycophenolate 500mg tablets. Take 1 tablet four times daily & Humira Pen 40mg/0.4ml. Inject 0.4ml every other week.
- Clinical Recommendation: No treatment needed
- Clinical Savings: $49,436 annual plan savings from this single clinical intervention
